{
  "docId": "019de071-f648-72d0-9c84-3373768bf908",
  "docSlug": "15eb2f0f83943ed61260bacd75adb779",
  "documentTitle": "ATAI | Investor Day Presentation Deck | 42 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 42,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_messages",
  "function": "frame_situation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f648-72d0-9c84-3373768bf908/22",
  "deckHref": "/decks/019de071-f648-72d0-9c84-3373768bf908",
  "deckJsonHref": "/decks/019de071-f648-72d0-9c84-3373768bf908.json",
  "deckAnchorHref": "/decks/019de071-f648-72d0-9c84-3373768bf908#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.8,
        "y": 0.55
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce7f2aa2-219c-4717-aac8-9edd7b3339fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Initial indication: Cognitive Impairment Associated with Schizophrenia (CIAS) is characterized by episodic learning and memory deficits – no approved treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e7acc44-8d28-453a-b41e-60a1f9c58904",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "Human Phase 1 + 2 data show replicated, clinically significant learning and memory effects, consistent with broad pre-clinical pro-cognitive data",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34fde112-8200-4bde-b4c9-ce273aa78cb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "De-risked pharma developed product in-licensed with impressive ($100M) pre-clinical & clinical data package",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "918d0556-86d7-4aac-8098-0e029c728f3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "Well tolerated (>500 subjects dosed), centrally acting oral drug",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8cae463-38d5-44da-8018-c4dd0b453164",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "RL – 007: a de-risked pro-cognitive treatment for CIAS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdf7b6e6-576d-4ecc-8d4d-5798e3692fa4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b0302666-f8ae-48d4-90d4-4b396f6deb3a",
      "evidence": "list/bullet: Initial indication: Cognitive Impairment Associated with Schizophrenia (CIAS) is characterized by episodic learning and memory deficits – no approved treatment",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 21,
      "beatId": "7effda0b-3140-4201-ba8c-40b7efb15914",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 21-28 present RL-007 as a potential solution, highlighting its de-risked profile, positive pre-clinical results, and promising phase 2a data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 21,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "21a21e3f-dd77-4b2c-ac26-e2f61f7dcb24",
      "evidence": "Slides 21-22 present RL-007 as a potentially game-changing compound, providing an aha moment for the audience",
      "position": 1,
      "objective": "What is the potential of RL-007 to address CIAS?",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}